Background – PCSK9 Inhibitors and New Cholesterol Treatment Guidelines Amgen and Sanofi / Regeneron presented phase III LDL-C (‘bad cholesterol’) lowering data for their respective PCSK9 inhibitors (evolocumab and alirocumab,…
We expect 1Q14 health services demand growth (y/y, nominal) of 3.4%, the product of 2.4% growth in intensity demand and 1.0% growth in nominal pricing (Exhibit 1). Our estimate of…
The age-mix of health insurance exchange (HIE) enrollees (Exhibit 1, green columns) skews older than the age-mix we believe is necessary (Exhibit 1, grey columns) to avoid adverse selection, i.e.…
Premise and rationale Share prices of drug and biotech stocks arguably can be broken down into two major components: the capital markets’ estimates of the value of assets that are…